Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Routine +

Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program

Bausch + Lomb ESG Push Overshadows Flat Margins as Debt Refinancing Looms

By The Northwire Desk — AI Analysis Apr 16, 2026 · 07:00 BLCO · 23.14 BAUSCH + LOMB CORPORATION
Executive Summary
  • The most recent release (April 16, 2026) announces a sustainability milestone for the "ONE by ONE" Recycling program, collecting over 725,000 pounds of contact lens materials in the U.S. and 78,000+ pounds in Canada.
  • The initiative involves collaboration with TerraCycle and includes a charitable donation component ($1 per pound to Optometry Giving Sight).
  • Preceding news (April 8) details FDA 510(k) clearance for Bi-Blade+ dual-port vitrectomy cutter, improving cutting speed by ~67% and reducing vibration.
  • April 7 news confirms European commercial launch of enVista Envy premium intraocular lens with strong clinical data on dysphotopsia tolerance.
  • February 18 earnings release reported FY2025 revenue of $5.101B (+6% YoY) but widened GAAP net loss to $360M; Adjusted EBITDA was essentially flat at $858M.
  • December 2025 news announced a $2.8B refinancing of term loans with extended maturities and reduced interest margins.
Material Impact
  • The April 16 recycling announcement is Routine - Positive but financially immaterial; it does not impact revenue, margins, or cash flow significantly enough to alter valuation models.
  • The April 8 FDA clearance for Bi-Blade+ represents incremental innovation in the Surgical segment rather than a disruptive new product category; expected to support existing Stellaris Elite system sales.
  • The enVista Envy launch expands premium IOL availability in Europe, aligning with management's growth strategy but faces competition from established players like Alcon and Johnson & Johnson.
  • Financial performance remains mixed: Revenue growth is consistent (5-7% guidance), yet GAAP losses are widening due to tax provisions and refinancing fees, raising concerns about underlying profitability quality.
  • Adjusted EBITDA flatness YoY despite revenue growth indicates margin compression or increased cost of sales, which contradicts the "financial excellence" narrative presented by management.
BLCO · Price
Company Overview
  • Bausch + Lomb operates across Vision Care (contact lenses, eye vitamins), Surgical (laser systems, IOLs), and Pharmaceuticals (dry eye treatments).
  • Flagship Project: enVista platform of intraocular lenses; the new Envy model targets premium diffractive vision correction in Europe.
  • Secondary Flagship: Elios laser system for glaucoma treatment; currently CE-marked but awaiting U.S. commercial launch, representing a key growth lever.
  • Consumer Brand: MIEBO dry eye drops are a major revenue contributor ($112M Q4 sales), driving Vision Care segment growth.
Read the original news release →

More from BAUSCH + LOMB CORPORATION

Jul 01, 2026 · 07:00

Dry Eye Survey Reinforces Premium Pricing Power, But Lacks Catalyst to Break Recent Consolidation

Other Jun 01, 2026 · 06:59

Bausch + Lomb Expands Dry Eye Portfolio with Preservative-Free Blink Launch; Execution on $7B Pipeline Continues Amid Margin Expansion

Financings May 19, 2026 · 07:00

Bausch + Lomb Executes H1 2026 Launch Plan Amidst Margin Expansion Push

Other May 07, 2026 · 07:00

Bausch + Lomb Expands Surgical Portfolio with European Bi-Blade+ Launch Amidst Guidance Raise

Other May 06, 2026 · 07:15

Bausch + Lomb Pipeline Webinar Confirms Long-Term Growth Narrative, But Near-Term Surgical Headwinds Persist Despite Q1 Guidance Raise

Other Apr 30, 2026 · 07:00

Bausch + Lomb Pipeline Validation Follows Q1 Guidance Raise Amidst Margin Expansion

Other